This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Cholecalciferol for Vitamin D in Adult Cystic Fibrosis (CF) Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
St. Michael's Hospital, Toronto
ClinicalTrials.gov Identifier:
NCT00685971
First received: May 27, 2008
Last updated: November 20, 2014
Last verified: July 2011
  Purpose
The main aim of the research question to test the primary hypothesis of this study, namely, Does 12 weeks of an additional 5000 IU daily of cholecalciferol increase serum 25OHD levels in adults with Cystic Fibrosis (CF) who have vitamin D deficiency relative to placebo?

Condition Intervention
Cystic Fibrosis Vitamin D Deficiency Dietary Supplement: 5000 IU of cholecalciferol Dietary Supplement: placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized Placebo-Controlled Trial of Cholecalciferol for Vitamin D Deficiency in Adults With Cystic Fibrosis

Resource links provided by NLM:


Further study details as provided by St. Michael's Hospital, Toronto:

Primary Outcome Measures:
  • The primary outcome measure for this study is the change in mean serum 25OHD levels between the two groups [ Time Frame: 12 weeks ]

Secondary Outcome Measures:
  • Mean change from baseline for pulmonary function testing (FEV1 and FVC) [ Time Frame: 12 weeks ]
  • Mean change from baseline in serum calcium levels [ Time Frame: 12 weeks ]
  • Mean change from baseline in parathyroid hormone levels [ Time Frame: 12 weeks ]
  • Mean change from baseline in creatinine levels [ Time Frame: 12 weeks ]
  • Change in the proportion of subjects whose 25OHD vitamin levels are above 75 nmol/L [ Time Frame: 12 weeks ]
  • A subgroup analysis by pancreatic status will be done to assess the impact of this factor on serum 25OHD levels [ Time Frame: 12 weeks ]

Estimated Enrollment: 200
Study Start Date: December 2008
Study Completion Date: July 2013
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Vitamin D
vitamin
Dietary Supplement: 5000 IU of cholecalciferol
5 drops taken once daily for 12 weeks
Placebo Comparator: Placebo Dietary Supplement: placebo
5 drops once daily for 12 weeks

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. older than 18 years of age
  2. diagnosis of CF by sweat testing/genetics
  3. vitamin D deficiency defined as a serum 25OHD level < 75 nmol/L
  4. on stable baseline vitamin D supplementation for at least 2 months. Standard vitamin D supplementation (cholecalciferol) in CF includes 800 IU daily for individuals with pancreatic insufficiency and 400 IU daily for those with pancreatic sufficiency

Exclusion Criteria:

  1. Individuals with known hypercalcemia or renal stones
  2. psychiatric history
  3. use of tanning beds/travel to sunny location within the last 2 months
  4. lung transplantation
  5. pregnancy or lactating women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00685971

Locations
Canada, Ontario
St. Michael's Hospital
Toronto, Ontario, Canada, M5B 1W8
Sponsors and Collaborators
St. Michael's Hospital, Toronto
Investigators
Principal Investigator: Anne Stephenson, Dr. St. Michael's Hospital, Toronto
  More Information

Responsible Party: St. Michael's Hospital, Toronto
ClinicalTrials.gov Identifier: NCT00685971     History of Changes
Other Study ID Numbers: SMH 07-036
Study First Received: May 27, 2008
Last Updated: November 20, 2014

Keywords provided by St. Michael's Hospital, Toronto:
Cystic Fibrosis
Vitamin D deficiency

Additional relevant MeSH terms:
Fibrosis
Cystic Fibrosis
Vitamin D Deficiency
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Avitaminosis
Deficiency Diseases
Malnutrition
Nutrition Disorders
Vitamin D
Ergocalciferols
Vitamins
Cholecalciferol
Micronutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents

ClinicalTrials.gov processed this record on June 26, 2017